RT Book, Section
A1 Ahmed, Sairah
A1 Parmar, Simrit
A1 Neelapu, Sattva
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
A2 Rieber, Alyssa G.
SR Print(0)
ID 1190833793
T1 Cellular Therapy for Lymphoma
T2 The MD Anderson Manual of Medical Oncology, 4e
YR 2022
FD 2022
PB McGraw Hill Education
PP New York, NY
SN 9781260467642
LK hemonc.mhmedical.com/content.aspx?aid=1190833793
RD 2024/04/25
AB KEY  CONCEPTSAdoptive  cellular  immunotherapy  with  chimeric  antigen  receptor  (CAR)  T-cell  therapy  has  changed  the  treatment  landscape  of  B-cell  non-Hodgkin  lymphoma  (NHL),  especially  for  aggressive  B-cell  lymphomas.CAR  T-cell  therapy  is  FDA  approved  for  poor-risk  diffuse  large  B-cell  lymphoma  (DLBCL)  and  mantle  cell  lymphoma  (MCL)  when  no  other  effective  treatment  options  are  available,  and  it  has  shown  long-term  remissions  in  up  to  40%  of  patients  without  other  treatment  options.CAR  T-cell–related  toxicities  remain  important  potential  complications  of  this  therapy,  which  includes  acute  toxicity  with  cytokine-release  syndrome  and  neurotoxicity,  as  well  as  long-term  complications  such  as  infection  and  cytopenias.Relapse  after  CAR  T-cell  therapy  remains  a  significant  challenge  and,  although  the  exact  mechanisms  causing  tumor  escape  remain  unknown,  relapse  after  CAR  T-cell  therapy  that  targets  the  CD19  antigen  can  be  categorized  broadly  as  (1)  antigen  loss,  (2)  lack  of  CAR  T-cell  persistence,  or  (3)  host-specific  factors.Real-world  analyses  highlight  that  patient  response  rates  and  toxicity  profiles  were  similar  to  the  pivotal  trials,  while  being  inclusive  of  patients  who  would  not  fit  within  the  highly  restrictive  parameters  of  clinical  trials.Trials  are  ongoing  in  multiple  lymphoma  histologies  including  T-cell  lymphoma  and  Hodgkin  lymphoma,  in  addition  to  novel  autologous  CAR  constructs  and  allogeneic  CAR  T  and  natural  killer  (NK)  cells.